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Abstract Pharmacokinetics of ketoprofen (KTP) enanti-
omers has been studied in patients with rheumatoid arthritis
(RA) following administration of a single oral dose of
100 mg rac-KTP during multidrug therapy taking into con-
sideration the genotype of RA patients Concentrations of
(-)-R and (?)-S enantiomers of KTP in plasma, urine and
synovial ﬂuid samples were determined using a validated
HPCE method. The genotype of the patients was analyzed
using PCR-RFLP method to determine the polymorphic
variantsofgenescodingCYP2C8andCYP2C9isoenzymes.
The levels of KTP enantiomers in synovial ﬂuid at 4 h
following administration were insigniﬁcantly greater [(-)-
R = 1.34 ± 0.91 mg/L; (?)-S = 1.38 ± 0.91 mg/L] than
in plasma [(-)-R = 1.15 ± 0.95 mg/L; (?)-S = 1.22 ±
0.95 mg/L]. The values of AUC0-? were 11.89 ± 5.00 and
10.92 ± 4.10 mg h/L for (-)-R and (?)-S enantiomer,
respectively,andwerelowercomparedwithdataobtainedin
healthyvolunteersfollowingadministrationofthesamedose
of rac-KTP. But, no statistically signiﬁcant differences were
observed also for Cmax, Cl, Vd, t0.5 and MRT of KTP enan-
tiomers. The total percentage of unchanged KTP eliminated
with urine of RA patients was in the range of 30–50% of
the administered dose. Though RA patients represented
the same wild genotype, quite signiﬁcant variabilities
(Cl(-)-R = 2.37–13.50 L/h and Cl(?)-S = 2.44–9.90 L/h)
existed in the pharmacokinetics parameters of KTP. We
concluded that KTP data obtained from healthy volunteers
cannot be sufﬁcient to predict disposition of KTP enantio-
mers in RA patients, especially when undergoing long-term
multidrug therapy.
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1 Introduction
Ketoprofen (KTP) belongs to the group of 2-arylpropionic
acid (2-APA) derivatives and is one of the most commonly
used non-steroidal anti-inﬂammatory drugs (NSAIDs).
Generally, it is prescribed for the treatment of inﬂamma-
tion and pain caused by rheumatoid arthritis (RA) and
osteoarthritis. The 2-APA propionic acid side chain pos-
sesses an asymmetric a-carbon and therefore KTP occurs
as (-)-R and (?)-S enantiomers. Its therapeutic activity is
associated with inhibition of the cyclooxygenase (COX-1,
COX-2) with a reduction of prostaglandin production such
as PGE2, PGF2a in tissue (Baek et al. 2002). Although the
pharmacological activity of KTP resides principally in the
(?)-S enantiomer (eutomer), it is marketed mainly in the
form of a racemic (rac-) mixture. The (-)-R enantiomer of
some profens undergo a unidirectional chiral inversion to
the (?)-S enantiomer via the formation of its acyl CoA
thioester. In humans, the chiral inversion of (-)-R to
(?)-S-KTP is limited to approximately 10% (Rudy et al.
1998). It may be one of the reasons for small differences
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reported by most of the literature data. The data regarding
pharmacokinetics of KTP are based mostly on the studies
performed in healthy volunteers. Ishizaki et al. (1980)
observed signiﬁcant differences in Cmax, tmax, Cl and Vd
following oral, intramuscular and rectal administration of
100 mg rac-KTP to healthy volunteers. The kinetics of the
(-)-R-KTP were studied following the administration of
both the racemate and the (-)-R enantiomer to healthy
volunteers. There were small (\5%) differences between
AUC of the enantiomers, and the elimination rate constant
of (-)-R-KTP was gender dependent (Rudy et al. 1998).
More recently, pharmacokinetic studies of KTP enantio-
mers in healthy volunteers involved administration of
standard and sustained release tablets with rac-KTP
(Gło ´wka 2002; Gło ´wka and Karaz ´niewicz 2004). Signiﬁ-
cant differences in the pharmacokinetic parameters of both
formulations were observed, but not between (-)-R and
(?)-S enantiomers within one formulation (Gło ´wka 2002).
Although KTP has a proven effectiveness in the treatment
of arthritic diseases, data regarding pharmacokinetics of
KTP enantiomers in patients with RA are limited. Skeith
et al. (1993) examined the effect of dose, renal function and
the presence of arthritis on the stereoselective kinetics of
the drug. No signiﬁcant differences in pharmacokinetic
parameters were found between non-arthritic and arthritic
subjects. Moreover, Foster et al. (1998) found no signiﬁ-
cant differences in KTP pharmacokinetics between young
and elderly patients with arthritis. Park et al. (2001)
observed differences in pharmacokinetics of racemic KTP
in plasma and synovial ﬂuids in arthritic patients at steady
state after 100-mg oral doses. Although, pharmacokinetics
of KTP enantiomers in patients with RA may be affected
by impaired metabolism of the drug or co-administered
medicines, there are no data regarding inter-individual
variability of pharmacokinetic parameters of KTP enanti-
omers caused by these factors. Recent studies indicate that
impaired metabolism of enantiomers of 2-APA derivatives
may be caused by genetic polymorphism of drug-metabo-
lizing enzymes, CYP2C8 and CYP2C9 (Garcia-Martin
et al. 2004; Karaz ´niewicz-Łada et al. 2009). Although the
main metabolic pathway of KTP enantiomers is direct
glucuronidation, the drug is a substrate for CYP450 iso-
enzymes which are responsible for its hydroxylation
(Rodrigues 2005). Currently, there are no literature data on
the effect of genetic polymorphism of CYP450 enzymes on
pharmacokinetics of KTP enantiomers.
The paper presents the results of pharmacokinetic
studies of KTP enantiomers in patients with RA with ref-
erence to genetic polymorphism and long-term multidrug
therapy. The outcomes may be helpful for improving
therapy by settlement of individual KTP dosing for patients
with RA.
2 Materials and methods
2.1 Chemicals
A racemic mixture of KTP, (?)-S-KTP (optical purity, o.p.
99.0%), (?)-S-naproxen [(?)-S-NPX] (o.p. 98.0%) and
heptakis 2,3,6-tri-O-methyl-b-cyclodextrin (TMbCD) was
obtained from Sigma (St. Louis, MO, USA); 85% of
orthophosphoric acid (P.O.Ch., Gliwice, Poland) and tri-
ethanolamine (Sigma-Aldrich Chemie, Steinheim, Ger-
many) were of reagent grade. b-glucuronidase solution
from Helix pomatia (containing 1,000–5,000 U/ml of sul-
fatase and 100,000 U/ml of b-glucuronidase) were from
Sigma; 1.0 M and 0.1 M NaOH, water for HPCE (Agilent
Technologies, Waldbronn, Germany), potassium dihydro-
gen phosphate (Xenon, Ło ´dz ´, Poland) and disodium
hydrogen phosphate anhydrous (Fluka, Buchs, Switzer-
land) were used.
2.2 Equipment and CZE conditions
Determination of KTP enantiomers was performed on an
Agilent model
3DCE apparatus (Agilent Technologies,
Waldbronn, Germany) with UV detector set at 253 nm.
Extracted samples were automatically injected using
hydrodynamic injection at the anode. The temperature of
the capillary was maintained by a thermostatic system at
30C. The separation was performed in a fused silica cap-
illary, 40 cm 9 50 lm i.d., 31.5 cm to the detector. The
apparatus was equipped with ChemStation software. All
experiments were carried out at 25 kV and 50 9 5 mbar s
injection (10 nL injected volume). The enantiomers were
determined using a 0.02 M background electrolyte (BGE)
containing 0.05 M TMbCD. BGE of pH 5 was prepared as a
mixture of appropriate volumes of aqueous 0.2 M ortho-
phosphoric acid and 0.2 M triethanoloamine. The solution
was passed through 0.45 lm ﬁlter and degassed by ultra-
sound before insertion into the capillary.
2.3 Determination of KTP enantiomers in plasma,
synovial ﬂuid and urine
For determination of KTP enantiomers in human plasma,
synovial ﬂuid and urine, the above CZE method was used.
Volumes of 0.5 mL of plasma or synovial ﬂuid were spiked
with 50 lL of 20 mg/L (?)-S-NPX solution as internal
standard (IS). The resulting mixture was acidiﬁed with
0.2 mL of 1.0 M orthophosphoric acid and extracted with
2 mL of dichloromethane. The mixture was shaken for
10 min at an amplitude of 1 cm and a frequency of 300
cycles min
-1, subsequently cooled at 4C for 20 min and
centrifuged for 5 min to attain proper separation of the two
phases. The lower organic layer was transferred to glass
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123tubes and evaporated to dryness at 40C under a gentle
nitrogen ﬂow. To determine the total (free and conjugated
with glucuronic acid) amounts of KTP enantiomers
excreted in urine, 100 lL of urine was mixed with 1 mL of
phosphate buffer, pH 7.4 and 5 lLo fb-glucuronidase.
Then, the mixture was incubated at 37C for 20 h. Sub-
sequently, the enzymatically treated urine samples were
spiked with 50 lL of the IS solution and extracted with
dichloromethane according to the procedure described
above. The dry residue was dissolved in 50 lL of methanol
and 150 lL of demineralized water and injected into the
silica capillary ﬁlled with BGE.
The CZE method, before use for the analysis of KTP
enantiomers in biological ﬂuids of RA patients, has been
validated (Gło ´wka and Karaz ´niewicz-Łada 2008).
2.4 Pharmacokinetic and genotyping analysis
The investigations were approved by the Ethics Committee
at Poznan University of Medical Sciences. Eleven patients
with RA (8 female, 3 male) aged between 39 and 73 years
(mean ± SD: 50 ± 10 years) of weight 64 ± 13 kg were
included in this study. All subjects were white Polish indi-
viduals treated atthe Poznan Rheumatology Centerin S ´rem.
Inclusion criteria were: male or female; puncture was
required because the presence of the exudative liquid
handicapped the activity of the joint. Patients with RA
also suffered from other diseases, such as hypertension
(5 patients), osteoporosis (4 patients), diabetes (1 patient),
ischemic heart disease (1 patient), chronic lymphocytic
thyroiditis (1 patient) and knee joint inﬂammation (2
patients).Fourpatients sufferedfrommorethanonedisease.
Rheumatoid factor (RF) was determined in the plasma of
nine subjects. All patients were fully informed of the nature
of these studies, signed informed consent forms and could
discontinuetheirparticipationatanytime.Subjectsreceived
a single tablet of 100 mg racemic KTP (Lek, Ljubljana,
Slovenia). Patients were also receiving additional medicines
due to their medical conditions (Table 1). None of these
drugs or their metabolites were found to interfere with the
analysisofKTP.Blood sampleswerecollectedimmediately
prior to administration of rac-KTP and at 2.0, 4.0 and 6.0 h
postdrug administration; synovial ﬂuid samples were taken
at 4 h postdrug administration. Urine samples were also
collected into separate containers over 24 h after adminis-
tration. The volume of each urine sample was measured and
after centrifugation kept frozen at -20C until required for
analysis. Moreover, from eight patients blood samples were
collected in EDTA blood tubes for the genotype analysis.
TheconcentrationsofKTPenantiomersinplasmawereused
forthecalculationofpharmacokineticparametersusingone-
compartmental analysis. The Topﬁt 2.0 software package
(Heinzel et al. 1993) was used for the pharmacokinetic cal-
culations. AUC0-? was estimated by trapezoidal rule with
extrapolation to inﬁnity using Cn/ke where Cn was the last
measurable concentration in plasma and ke was the ﬁrst-
order elimination rate constant. The maximum plasma
concentration (Cmax) and the time to reach Cmax (tmax) were
Table 1 Clinical characteristics of patients with rheumatoid arthritis
Initials Age Sex Weight [kg] RF [IU/ml] Medications administered simultaneously
J.M. 48 M 83 12 Amlodipine, azathioprine, diclofenac, methylprednisolone,
metoprolol, omeprazole, sulphasalazine
G.P. 40 M 86 12 Sulphasalazine
R.I. 54 F 58 0 Alendronate, methotrexate, methylprednisolone,
sulphasalazine, triamcinolone
I.N. 48 F 56 12 Diclofenac, methylprednisolone, omeprazole
M.Z. 39 F 73 12 Folic acid, methylprednisolone, omeprazole
A.R. 45 F 48 nd Cyclosporine, folic acid, methotrexate, methylprednisolone
M.B. 52 F 66 0 Folic acid, methotrexate, molsidomine, naproxen,
triamcinolone, trimetazidine dihydrochloride
H.D. 58 F 56 96 Alendronate, diclofenac, insulin, methylprednisolone,
sulphasalazine, triamcinolone
S.G. 73 F 58 384 Acetylsalicylic acid, amlodipine, diclofenac, folic acid,
isosorbide mononitrate, methotrexate, methylprednisolone,
metoprolol, omeprazole, triamcinolone
H.B. 58 F 49 nd Alendronate, azathioprine, diclofenac, lorazepam,
methylprednisolone
R.P. 41 M 76 24 Bisoprolol, methotrexate, methylprednisolone, sulphasalazine
Mean ± SD 50 ± 10 64 ± 13
nd no data
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123calculated. Plasma drug clearance (Cl/F) was obtained
dividing the dose (D) of each enantiomer by AUC0-?.
The volume of distribution (Vd/F) was estimated from
D/(AUC0-?ke). Urinary amounts of KTP enantiomers
(free ? conjugated) were used to assess the percentage of
eliminated dose of the drug.
Analysis of patients’ genotype was performed using
genomic DNA extracted from peripheral blood lympho-
cytes by the salting-out method. Then, polymerase chain
reaction-restriction fragment length polymorphism (PCR-
RFLP) technique was used to analyze polymorphic variants
of CYP2C8 and CYP2C9 (Karaz ´niewicz-Łada et al. 2009).
3 Results and discussion
3.1 Genotyping for CYP2C8 and CYP2C9 alleles
To investigate the genetic basis for the variability in KTP
pharmacokinetics, CYP2C8 and CYP2C9 genotypes were
analyzed in the studied population. Conditions for genotype
analysis were previously applied for determination of mutant
alleles responsible for impaired metabolism of ibuprofen
(IBP) enantiomers in healthy volunteers (Karaz ´niewicz-Łada
etal.2009).InthestudiedgroupofeightpatientswithRA,no
mutantallelesweredetectedandallthesesubjectsappearedto
possess a wild-type genotype.
3.2 Pharmacokinetic parameters
After administration of rac-KTP, concentration values of
(-)-R-KTP in plasma, during the elimination phase were
lower than those of the (?)-S enantiomer, but the differ-
ences were not statistically signiﬁcant (Fig. 1). In previous
studies performed on healthy volunteers (Gło ´wka 2002),
the plasma levels of (-)-R enantiomer were higher than for
(?)-S-KTP, especially during the absorption and distribu-
tion phase, but concentration values during the elimination
process were slightly higher for (?)-S-KTP as in RA
patients. These data are consistent with unidirectional
inversion of the (-)-R enantiomer to the (?)-S-KTP.
However, according to literature, the chiral inversion of
(-)-Rto(?)-S-KTPislimitedtoonly10%(Rudyetal.1998).
Concentrations of KTP enantiomers in synovial ﬂuid at 4 h
post-administration of the drug are presented in Fig. 2. The
values were greater [(-)-R = 1.34 ± 0.91 mg/L; (?)-S =
1.38 ± 0.91 mg/L] than in plasma [(-)-R = 1.15 ±
0.95 mg/L; (?)-S = 1.22 ± 0.95 mg/L], but the differ-
ences were not statistically signiﬁcant (Fig. 1). It means
that in the elimination phase, plasma and synovial levels
are comparable. Then from plasma data of KTP enantio-
mers, we can predict their level in the synovial ﬂuid. Dif-
ferent results were obtained in arthritic patients by Park
et al. (2001), where the time course of the racemic KTP
concentration in the synovial ﬂuid was different from the
plasma concentration time proﬁle. The AUC0-? was
11.89 ± 5.00 and 10.92 ± 4.10 mg h/L for the (-)-R and
(?)-S enantiomers, respectively, and was decreased in
about 30% in comparison to the data obtained previously
from healthy volunteers following administration of the
same dose of rac-KTP (Table 2). One of the possible rea-
sons for the lower bioavailability of KTP enantiomers
could be the reduced gastrointestinal function, character-
istic of elderly patients. The food should be also considered
in these deliberations on decreasing of KTP bioavailability.
Caille ´ et al. (1989) concluded that plasma concentrations of
rac-KTP after administration of a single and multiple dose
were affected by food, with a decrease of greater than 40%
in bioavailability. Moreover, drugs co-administered with
NSAIDs, such as the proton pump inhibitor—omeprazole,
may affect absorption of the substance from the GI tract,
and subsequently lower the fraction of the drug that reaches
Fig. 1 Mean concentration of KTP enantiomers in plasma and
synovial ﬂuid versus time in patients with RA following administra-
tion of a single dose of 100 mg rac-KTP
Fig. 2 Concentration of KTP enantiomers in synovial ﬂuid in 11
patients with RA at 4 h following administration of 100 mg rac-KTP
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123the systemic circulation. In the present studies, four
patients were taking omeprazole along with KTP, but this
did not affect Cmax and AUC of the KTP enantiomers. The
t0.5 values of (-)-R and (?)-S enantiomers of KTP did not
differ signiﬁcantly and they amounted to 1.66 ± 0.43 and
1.82 ± 0.59 h, respectively. The values are similar to lit-
erature data obtained following administration of 150 mg
rac-KTP to patients with RA, where elimination half-life
was in the range of 2.55 ± 0.48 and 2.95 ± 0.54 h for
(-)-R and (?)-S-KTP, respectively (Skeith et al. 1993).
Also, no statistically signiﬁcant differences were observed
for other pharmacokinetic parameters of KTP enantiomers,
such as Cmax, Cl, Vd and MRT. It can due to the fact that
chiral inversion of (-)-R to (?)-S-KTP is negligible.
The differences between pharmacokinetic parameters
obtained from healthy volunteers and RA patients exist, but
only those for AUC0-?of both KTP enantiomers and Cl of
(?)-S-KTP were statistically signiﬁcant (Table 2). The
higher values of Cl and Vd in RA patients in comparison to
healthy volunteers may be a result of changes in drug
protein binding. The clearance of KTP, which is a drug
with low hepatic extraction, is proportional to the unbound
fraction of the drug. Thus, protein binding is an important
determinant for pharmacokinetic parameters, such as Cl
and Vd. If the free fraction of KTP in blood is increased, the
Cl is also increased, resulting in smaller AUC. The ele-
vations in the free fraction of drug may be caused by
plasma protein displacement interaction, when the drug is
concurrently administered with other drugs that bind with
albumin. Plasma protein displacement is observed when
NSAIDs are given with methotrexate, oral anticoagulants,
antidiabetic agents and thyroid hormones (Mehanna 2003).
Moreover, many NSAIDs such as naproxen, suprofen and
fenoprofen have higher afﬁnity in the binding to the protein
than KTP (Bertucci 2001). The patients who participated in
the study also were taking drugs, such as methotrexate,
diclofenac, naproxen and acetylsalicylic acid, which have
the potential possibility to interact with albumin as the
displacers of KTP. Moreover, the free concentration of a
drug can change because of hypoalbuminemia. According
to the literature data, in RA patients the albumin level in
plasma is decreased (Niwa et al. 1990).
The percentage of KTP (free ? conjugated) eliminated
with urine of patients with RA was in the range of 30–50%
of the administered dose (Fig. 3). These values show that
the percentage of eliminated does of KTP enantiomers in
some cases were greater than literature data where
approximately 30% of the dose of KTP was recovered in
urine of patients with RA (Sallustrio et al. 1988). However,
this value is lower in comparison with the literature data
Table 2 Pharmacokinetic parameters of KTP enantiomers after administration of 100 mg rac-KTP to healthy volunteers (Gło ´wka 2002) and
patients with RA
Parameters (-)-R-KTP (?)-S-KTP
Patients with RA Healthy
volunteers
ANOVA Patients with RA Healthy
volunteers
ANOVA
a = 0.05 a = 0.05
t0.5 (h) 1.66 ± 0.43 1.84 ± 0.62 NS 1.82 ± 0.59 2.10 ± 0.73 NS
AUC0-? (lg h/ml) 11.89 ± 5.00 17.16 ± 2.30 p = 0.043 10.92 ± 4.10 16.43 ± 2.21 p = 0.014
Cl/F (L/h) 5.22 ± 3.11 2.96 ± 0.38 NS 5.19 ± 2.01 3.09 ± 0.40 p = 0.038
Vd/F(L) 12.88 ± 8.44 7.78 ± 2.80 NS 13.58 ± 6.70 9.14 ± 3.43 NS
MRT (h) 2.70 ± 0.82 3.08 ± 1.04 NS 3.07 ± 0.85 3.18 ± 1.08 NS
Fig. 3 Amounts of KTP
enantiomers excreted with urine
of patients with RA, presented
as percentage of administered
dose of each enantiomer.
Dashed lines represent the
levels of KTP excreted by
healthy volunteers (* Ishizaki
et al. 1980) or RA patients
(** Sallustrio et al. 1988)
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123regarding healthy volunteers, where the cumulative amount
of drug excreted with urine exceeded 63–75% of the dose
(Ishizaki et al. 1980). This difference was also observed by
Skeith et al. (1993). It was noticed that the mean percent-
age excretion of total KTP dose was up to 21% in the
arthritic patients, whereas in the non-arthritic subjects up to
72% was excreted. The main reason for this can be the
decreased bioavailability of KTP enantiomers observed in
patients with RA. Moreover, reduced urinary excretion can
be caused by enhanced enterohepatic circulation of con-
jugated KTP enantiomers in the elderly and subsequent
biliary excretion (Sallustrio et al. 1988). Skeith et al.
(1993) observed inter-subject variation of pharmacokinet-
ics in the studied group of arthritic and non-arthritic
patients, connected probably with age-related physiologic
changes in the elderly. In our study, the group of patients
with RA also exhibited a wide variability in the values of
pharmacokinetic parameters, especially those characteriz-
ing phenotype (Cl, AUC, t0.5). A wide range of clearance
values observed in patients (Fig. 4) may suggest alteration
in patients’ genotype. However, eight subjects with a wild-
type genotype and the values of Cl observed in three
patients, in whom genotype was not determined, do not
suggest the presence of any mutation. The main reason for
inter-individual variability of pharmacokinetics in the
studied group of patients with RA seems to be physiolog-
ical function of the organs responsible for metabolism and
elimination of the drug, which may be changed. Moreover,
the inﬂuence of co-administered drugs on the plasma pro-
tein binding of KTP enantiomers cannot be ruled out.
4 Conclusions
We investigated the pharmacokinetics of KTP enantiomers
under clinical conditions. To our knowledge, for the ﬁrst
time chiral pharmacokinetics of KTP has been estimated
taking into consideration the genotype of RA patients. Our
results conﬁrmed that pharmacokinetic data of healthy
volunteers, especially AUC, cannot be sufﬁcient to predict
the therapeutic effect of the chiral drug in RA patients. We
conclude that inter-individual variability in pharmacoki-
netics of KTP enantiomers in patients with RA cannot be
explained by genetic polymorphism of CYP450 enzymes.
Because of decreased AUC in RA patients, during selection
of individual therapy to the patients, the effect of
co-administered drugs, type of pharmaceutical formula-
tions and physiological changes related to the age of the
patients and food should be taken into consideration.
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